London-listed Tekcapital (AIM:TEK) told investors on Monday that its portfolio company, Belluscura, has filed a new patent application for a technology which could be used to treat patients with Coronavirus.
Belluscura and its research partner, Separation Design Group, have filed a patent on an oxygen enrichment device and system for treating acute respiratory distress (ARDS) which occurs in the most serious cases of the Coronavirus.
The patent application covers novel integrated portable extracorporeal oxygenation and carbon dioxide removal systems, the UK intellectual property investment group noted.
This ‘next-generation’ portable ECMO technology will be used to remove carbon dioxide from and diffuse oxygen into a patient's blood outside the body which allows the lungs time to recover.
Shares in Tekcapital were trading 6.19% higher at 5.15p during Monday trading.
Belluscura, of which Tekcapital owns a 18.9% interest in, is focused on developing novel oxygen-based treatment platforms that can be adapted and applied in a wide range of markets.
In this case, the portable ECMO technology will be offered in instances where oxygen therapy and ventilator support -- current primary treatments of the infection -- are rendered ineffective.
"We are pleased to see the additional progress of Belluscura as it continues to strengthen its intellectual property in the oxygen therapy space to help patients afflicted with acute respiratory distress caused by the Coronavirus, said Clifford Gross, Executive Chairman of Tekcapital.
This year, Belluscura will launch its first product, the X-PLOR™ portable oxygen concentrator, into the respiratory treatment field in order to treat chronic obstructive pulmonary disease.
Tekcapital added that Belluscura is likely to receive FDA clearance for their portable oxygen concentrator within the next 90 days.
Follow News & Updates from Tekcapital here: